High-dose treatment of cathepsin B-activatable doxorubicin prodrug nanoparticles that induce tumor-specific immunogenic cell death for immunotherapy of melanoma with minimal systemic toxicity
Asian J. Pharm. Sci., Available online 13 January 2026 | https://doi.org/10.1016/j.ajps.2026.101123